Screener
Zymeworks ZYME Reportable Segment — Other research and development expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Zymeworks in its filing.
Tagged under the XBRL concept us-gaap:OtherResearchAndDevelopmentExpense.
The source filing: Zymeworks’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001937653-26-000047
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| ZW191 | 3,127 | 2,764 | 6,158 | 4,470 |
| ZW220 | (152) | 327 | (55) | 2,525 |
| ZW251 | 3,205 | 2,340 | 5,112 | 6,291 |
| Expense for other preclinical and research programs | 4,192 | 6,174 | 11,456 | 12,250 |
| Unallocated research and development expenses: | ||||
| Salaries and benefits and stock based compensation | 10,681 | 12,034 | 25,440 | 24,757 |
| Other research and development expense | 4,659 | 5,987 | 10,285 | 11,440 |
| Total research and development expenses | $27,435 | $34,449 | $61,892 | $70,187 |
Item 1. Financial Statements
FAQ
- What is Zymeworks's reportable segment — other research and development expense?
- Zymeworks (ZYME) reported reportable segment — other research and development expense of $4.66M in Q2 2026.
- How has Zymeworks's reportable segment — other research and development expense changed year-over-year?
- Zymeworks's reportable segment — other research and development expense decreased by 22.2% year-over-year, from $5.99M to $4.66M.
- What is the long-term trend for Zymeworks's reportable segment — other research and development expense?
- Over 3 years (2022 to 2025), Zymeworks's reportable segment — other research and development expense has grown at a 4.6% compound annual growth rate (CAGR), from $19.06M to $21.81M.
- What does reportable segment — other research and development expense mean?
- This metric captures miscellaneous research and development expenditures within the reportable segment that are not categorized as direct personnel or collaboration costs. It reflects the overhead and operational support expenses necessary to sustain the segment's drug discovery and clinical development pipeline.
Ask your AI about Zymeworks's reportable segment — other research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude